NEJM Evidence ¼Ò°³

HOME > The New England Journal of Medicine > NEJM Evidence ¼Ò°³

NEJM Evidence´Â NEJM ÃâÆǻ翡¼­ 2022³â °ø½Ä â°£ÇÑ ¿Â¶óÀÎ Àú³Î·Î¼­ Çõ½ÅÀûÀÎ ¿¬±¸¿Í ÀÓ»ó½ÃÇè ¼³°è ¹× ÀÓ»óÀû ÀÇ»ç°áÁ¤°ú °ü·ÃµÈ Âü½ÅÇÏ°í ´ë´ãÇÑ ¾ÆÀ̵ð¾î¸¦ Á¦½ÃÇÏ°íÀÚ ¹ßÇàµÇ¾ú½À´Ï´Ù. ¿¬±¸ÀÇ ÃÖÀü¼±¿¡¼­ ³ª¿Â ¾çÁúÀÇ ³í¹®À» °ÔÀçÇÏ°í, »õ·Î¿î ¹æ½ÄÀÇ ÀÓ»ó½ÃÇè ¼³°è¿Í ¼öÇàÀ» °ÅÃÄ º¸´Ù °­·ÂÇÑ ÀÓ»óÁõ°Å¸¦ »ý¼ºÇÒ ¼ö ÀÖ°Ô µ¶·ÁÇϸç, ÃæºÐÇÑ ±Ù°Å ¾øÀÌ ÀÓ»ó°áÁ¤ÀÌ ³»·ÁÁö´Â ºÐ¾ß¿¡ ´ëÇÑ ´ëÈ­¿Í ³íÀǸ¦ Ã˹߽ÃÅ°°í, ÀÓ»óÁõ°Å¿Í °ü·ÃÇØ º¸´Ù Á¤±³ÇÏ°í ÀÇ¹Ì ÀÖ´Â ¹æ½ÄÀ¸·Î ÀÇ»çµéÀÌ Âü¿©ÇÒ ¼ö ÀÖ°Ô À¯µµÇÔÀ¸·Î½á Àӻ󿬱¸¿Í ÀÓ»óÁø·á¿¡¼­ °ý¸ñÇÒ ¸¸ÇÑ ÁøÀüÀÌ ÀÌ·ïÁö°Ô ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ°í ÀÖ½À´Ï´Ù.

  • Tomorrow¡¯s Trial: È®½ÇÇÑ ±Ù°Å°¡ ºÎÁ·ÇÏÁö¸¸ ³Î¸® ¹Þ¾Æµé¿©Áö´Â Áø·á¿¡ ÁÖ¸ñÇÏ¿© ±× °£±ØÀ» ¸Þ¿ì±â À§ÇÑ ÀÓ»ó½ÃÇè Á¦¾È
  • Patient Platform: ÀÓ»ó½ÃÇè¿¡ Âü°¡ÇÑ È¯ÀÚÀÇ °æÇè°ú »ý°¢À» °øÀ¯
  • Trial by Fire: ÀÓ»ó½ÃÇè °ü°èÀÚ¿Í Æò·Ð°¡ °£ 5ºÐ Åä·ÐÀ» ÆÌij½ºÆ®·Î Á¦°ø
  • Stats, STAT!: Åë°èÀû °ËÅ並 ±â¹ÝÀ¸·Î Åë°è °³³äÀ» ¼³¸íÇÏ´Â °£·«ÇÑ ¾Ö´Ï¸ÞÀÌ¼Ç µ¿¿µ»ó Á¦°ø

Editor-in-Chief

Jeffrey Drazen, M.D.
  • Distinguished Parker B Francis Professor of Medicine
  • Harvard Medical School
  • NEJM Group Editor
  • Boston, Massachusetts, USA
  • Pulmonary and Critical Care Medicine

NEJM EvidenceÀÇ ±¸µ¶À» ¿øÇϽðųª ¹®ÀÇ »çÇ×ÀÌ ÀÖÀ¸½Ã¸é Äù½ºÆ®·Î ¿¬¶ôÇÏ¿© ÁֽʽÿÀ.